New analysis supports starting with VFEND for life-threatening fungal infections

October 25, 2005

NEW YORK, October 25, 2005 - A new analysis of treatment procedures for the potentially deadly fungal infection invasive aspergillosis suggests that making the right treatment decision as soon as possible after diagnosis may be crucial to survival.

The retrospective analysis, published in the Nov. 15 issue of Clinical Infectious Diseases, showed that patients who initially received Pfizer's antifungal agent VFEND® (voriconazole) were more likely to survive than patients who initially received amphotericin B deoxycholate. The analysis also showed that patients who started on VFEND were less likely to need salvage therapy than those on amphotericin B. Salvage therapy is treatment given after the infection has not responded to the initial treatment or if the patient cannot tolerate the initial medicine.

Invasive aspergillosis is a severe pulmonary infection that can occur in patients with weakened immune systems. The fatality rate for invasive aspergillosis is estimated to be 58 percent, but approaches 90 to 100 percent in patients whose infection has spread beyond the primary site.

"These high mortality rates for invasive aspergillosis underscore the importance of initial treatment for this often fatal infection," said Dr. Thomas F. Patterson, lead author of the analysis and professor of medicine at the University of Texas Health Science Center at San Antonio. "Our analysis demonstrates that voriconazole's efficacy and tolerability make it an important choice for first-line therapy."

About The Study

The Global Comparative Aspergillosis Study (GCAS) led to VFEND's 2002 approval for the first-line treatment of invasive aspergillosis and was the basis for this newly published analysis. In that study, 144 patients with confirmed or probable invasive aspergillosis were started on VFEND and 133 were started on amphotericin B. If the disease progressed or the patient was unable to tolerate initial therapy, treatment could be changed to salvage therapy, which was referred to in the trial as "other licensed antifungal therapy," or OLAT.

Treatment was considered successful if the infection improved or was cured after 12 weeks of total therapy. Therapies that were used as salvage therapy included lipid formulations of amphotericin B, itraconazole, a dose reduction in amphotericin B, and other systemic antifungal therapy.

Results of the Analysis

Patterson et al retrospectively analyzed the data from the GCAS to assess the effect of salvage therapy on patient outcomes. Their analysis showed that just over a third (36 percent) of patients in the VFEND group required subsequent salvage therapy, while more than three-quarters (80 percent) of patients in the amphotericin B group required salvage therapy.

In addition, it found that of those patients in either group who had to switch to salvage therapy, patients who started on VFEND had better outcomes:
  • Patients in the VFEND group, who were switched to OLAT, were more likely to survive than those in the amphotericin B group who took OLAT (48 percent versus 38 percent, respectively). (Overall survival in the GCAS was 71 percent in the Vfend group versus 58 percent in the amphotericin B group.)
  • Of patients who had to switch to OLAT due to drug intolerance, those treated initially with VFEND had a higher success rate than those in the amphotericin B group (50 percent versus 38 percent, respectively)
  • Of those who had to switch to OLAT due to their initial treatment not working for them, patients initially treated with VFEND had a higher success rate than those treated with amphotericin B group (26 percent versus 19 percent, respectively)

    In addition, 55 percent of patients treated with VFEND alone had a successful outcome, compared to four percent of those on amphotericin B alone. (The overall efficacy rate was 53 percent for patients initially treated with VFEND, versus 32 percent for patients initially treated with amphotericin B, regardless of whether OLAT was used.)

    It should be noted that lipid formulations of amphotericin B are often used due to their perceived reduction in toxicity. In the GCAS, the lipid formulations were the most commonly used OLAT (38 percent of patients who received OLAT). However, the subsequent analysis of that study demonstrated that this salvage therapy was effective in only 30 percent of patients in the amphotericin B group and 36 percent of patients in the VFEND group. This success rate decreased to 12 percent when lipid formulations of amphotericin B were used in patients following an initial insufficient clinical response to amphotericin B deoxycholate.

    "Our analysis concluded that in order to reduce mortality rates associated with invasive aspergillosis, we need to rethink the practice of relying on salvage therapy, including lipid formulations of amphotericin B, and focus more on making the right initial treatment decision," said Dr. Patterson.
    -end-
    About VFEND
    VFEND was discovered by Pfizer researchers and was developed to address the unmet medical need for more effective and better-tolerated options for patients at risk for serious fungal infections.

    VFEND is currently approved in the United States for the treatment of invasive aspergillosis, esophageal candidiasis, candidemia in nonneutropenic patients (those without low white blood cell counts) and certain Candida infections (disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds). VFEND is also approved as salvage therapy for fungal infections caused by pathogens Scedosporium apiospermum and Fusarium species.

    VFEND is the only IV/oral antifungal specifically indicated for the first-line treatment of mould and yeast infections. The ability to switch patients from IV to oral VFEND allows patients to remain on the same medication throughout the course of treatment, both on an inpatient and outpatient basis.

    Most frequently reported adverse events (all causalities) in therapeutic trials were visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache, sepsis, peripheral edema, abdominal pain and respiratory disorder. Treatment-related adverse events that most often led to discontinuation in clinical trials were elevated liver function tests (LFTs), rash and visual disturbances. VFEND treatment-related visual disturbances are common. The effect of VFEND on visual function is not known if treatment continues beyond 28 days.

    VFEND is contraindicated with terfenadine, astemizole, cisapride, pimozide, quinidine (since increased plasma concentrations for these drugs can lead to QT prolongation and rare occurrences of torsades de pointes), sirolimus, rifampin, rifabutin, carbamazepine, long-acting barbiturates, ergot alkaloids, efavirenz and ritonavir (400 mg q12h). There have been uncommon cases of serious hepatic reactions during treatment with VFEND (clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). LFTs should be evaluated at the start of and during the course of therapy. Patients have rarely developed serious cutaneous reactions, such as Stevens-Johnson syndrome, during treatment with VFEND.

    Full prescribing information available upon request or please visit www.pfizer.com or www.vfend.com.

    Edelman Public Relations

    Related Infection Articles from Brightsurf:

    Halving the risk of infection following surgery
    New analysis by the University of Leeds and the University of Bern of more than 14,000 operations has found that using alcoholic chlorhexidine gluconate (CHG) halves the risk of infection in certain types of surgery when compared to the more commonly used povidone-iodine (PVI).

    How plants shut the door on infection
    A new study by an international team including University of Maryland scientists has discovered the key calcium channel responsible for closing plant pores as an immune response to pathogen exposure.

    Sensing infection, suppressing regeneration
    UIC researchers describe an enzyme that blocks the ability of blood vessel cells to self-heal.

    Boost to lung immunity following infection
    The strength of the immune system in response to respiratory infections is constantly changing, depending on the history of previous, unrelated infections, according to new research from the Crick.

    Is infection after surgery associated with increased long-term risk of infection, death?
    Whether experiencing an infection within the first 30 days after surgery is associated with an increased risk of another infection and death within one year was the focus of this observational study that included about 660,000 veterans who underwent major surgery.

    Revealed: How E. coli knows how to cause the worst possible infection
    The discovery could one day let doctors prevent the infection by allowing E. coli to pass harmlessly through the body.

    UK study shows most patients with suspected urinary tract infection and treated with antibiotics actually lack evidence of this infection
    New research presented at this week's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands (April 13-16, 2019) shows that only one third of patients that enter the emergency department with suspected urinary tract infection (UTI) actually have evidence of this infection, yet almost all are treated with antibiotics, unnecessarily driving the emergence of antimicrobial resistance.

    Bacteria in urine doesn't always indicate infection
    Doctors should think carefully before testing patients for a urinary tract infection (UTI) to avoid over-diagnosis and unnecessary antibiotic treatment, according to updated asymptomatic bacteriuria (ASB) guidelines released by the Infectious Diseases Society of America (IDSA) and published in Clinical Infectious Diseases.

    Subsidies for infection control to healthcare institutions help reduce infection levels
    Researchers compared three types of infection control subsidies and found that under a limited budget, a dollar-for-dollar matching subsidy, in which policymakers match hospital spending for infection control measures, was the most effective at reducing the number of hospital-acquired infections.

    Dengue virus infection may cause severe outcomes following Zika virus infection during pregnancy
    This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.

    Read More: Infection News and Infection Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.